trovafloxacin has been researched along with zithromax in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (47.83) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, DT; Katz, L; Plattner, JJ | 1 |
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kluytmans, JA; Stolz, E; van Rijsoort-Vos, JH; Verbrugh, HA | 1 |
| Andrews, JM; Boswell, F; Brenwald, NP; Wise, R | 1 |
| Erwin, ME; Jones, RN; Worth, S | 1 |
| Hammerschlag, MR; Kutlin, A; Roblin, PM | 1 |
| Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV | 1 |
| Bouchillon, S; Johnson, J; Pontani, D; Washton, H | 1 |
| Johnson, DM; Jones, RN; Pfaller, MA | 1 |
| Breitschwerdt, EB; Davidson, MG; Gilger, B; Hancock, SI; Hegarty, BC; Papich, MG | 1 |
| Jousimies-Somer, H; Kanervo, A; Könönen, E; Salminen, K | 1 |
| Gentry, MJ; Olsen, KM; Preheim, LC; Snitily, MU; Yue, M | 1 |
| Coleman, EJ; Mandell, GL | 1 |
| Gentry-Nielsen, MJ; Olsen, KM; Preheim, LC; Snitily, MU; Yue, M | 1 |
| Sutton, SC | 1 |
| Atkins, HS; Brew, SD; Brooks, TJ; Jenner, DC; MacMillan, AP; Sefton, AM; Simpson, AJ; Spencer, S | 1 |
| Atkins, HS; Brooks, TJ; Kenny, DJ; Laws, TR; Sefton, AM; Simpson, AJ | 1 |
3 review(s) available for trovafloxacin and zithromax
| Article | Year |
|---|---|
New directions in antibacterial research.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacteria; Drug Resistance, Microbial; Molecular Sequence Data; Molecular Structure | 1996 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The use of gastrointestinal intubation studies for controlled release development.
Topics: Animals; Azithromycin; Colon; Delayed-Action Preparations; Dogs; Fluoroquinolones; Humans; Imidazoles; Intestinal Absorption; Intubation, Gastrointestinal; Naphthyridines; Permeability; Sertraline; Solubility; Sulfides | 2009 |
20 other study(ies) available for trovafloxacin and zithromax
| Article | Year |
|---|---|
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In-vitro activity of a new quinolone (CP-99,219) compared with ciprofloxacin, pefloxacin, azithromycin and penicillin against Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Fluoroquinolones; Gonorrhea; Humans; Microbial Sensitivity Tests; Naphthyridines; Neisseria gonorrhoeae; Pefloxacin; Penicillins | 1995 |
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteroides fragilis; Chlamydia; Ciprofloxacin; Clarithromycin; Doxycycline; Enterobacter; Erythromycin; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Naphthyridines; Piperazines; Pseudomonas aeruginosa; Quinolones; Streptococcus pneumoniae | 1997 |
Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical
Topics: Acetamides; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Azithromycin; Clavulanic Acids; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Naphthyridines; Oxazoles; Oxazolidinones; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality Control; Roxithromycin; Ticarcillin | 1996 |
In vitro activity of trovafloxacin against Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Chlamydophila pneumoniae; Doxycycline; Erythromycin; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin | 1997 |
Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Bites and Stings; Bites, Human; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Species Specificity; Wound Infection | 1998 |
Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Europe; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Moraxella catarrhalis; Naphthyridines; Pseudomonas aeruginosa; Respiratory System; Staphylococcus aureus; Streptococcus pneumoniae | 1998 |
Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Topics: Anti-Infective Agents; Azithromycin; Cephalosporins; Drug Therapy, Combination; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Pseudomonas aeruginosa; Xanthomonas | 1998 |
Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Capillary Permeability; DNA, Bacterial; Dogs; Doxycycline; Female; Fluoroquinolones; Guinea Pigs; Male; Naphthyridines; Polymerase Chain Reaction; Rickettsia rickettsii; Rocky Mountain Spotted Fever; Treatment Outcome | 1999 |
beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; beta-Lactamases; Child, Preschool; Female; Fluoroquinolones; Fusobacterium nucleatum; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Penicillin G; Tetracycline | 1999 |
Ethanol feeding does not affect the efficacy or pharmacokinetics of azithromycin, trovafloxacin, or ceftriaxone in a rat model of pneumococcal pneumonia.
Topics: Animals; Anti-Infective Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Ceftriaxone; Disease Models, Animal; Ethanol; Feeding Behavior; Fluoroquinolones; Leukocyte Count; Male; Naphthyridines; Neutrophils; Pneumonia, Pneumococcal; Rats; Rats, Sprague-Dawley | 1999 |
Activities of antimicrobial agents against intracellular pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Fluoroquinolones; Gentamicins; Humans; Ketolides; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Penicillin G; Quinolines; Rifampin; Streptococcus pneumoniae; Tumor Cells, Cultured | 2000 |
Effect of cirrhosis on antibiotic efficacy in a rat model of pneumococcal pneumonia.
Topics: Animals; Azithromycin; Biological Availability; Blood Chemical Analysis; Bronchoalveolar Lavage Fluid; Ceftriaxone; Disease Models, Animal; Drug Therapy, Combination; Fluoroquinolones; Injections, Subcutaneous; Liver Cirrhosis; Male; Naphthyridines; Pneumonia, Pneumococcal; Random Allocation; Rats; Rats, Sprague-Dawley; Reference Values; Risk Assessment; Sensitivity and Specificity; Survival Rate | 2005 |
Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Brucella melitensis; Brucellosis; Colony Count, Microbial; Disease Models, Animal; Female; Fluoroquinolones; Humans; Mice; Mice, Inbred BALB C; Naphthyridines; Piperazines; Spleen | 2010 |
Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Burkholderia pseudomallei; Disease Models, Animal; Female; Fluoroquinolones; Humans; Melioidosis; Mice; Mice, Inbred BALB C; Naphthyridines; Piperazines; Survival Analysis | 2010 |